Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infection rate among SLE patients receiving intravenous cyclophosphamide at Chonburi Hospital
TCTR20250428002Completed
- Sponsor
- Principal Investigator
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide in systemic lupus erythematosus (SLE), sponsored by Principal Investigator. Primary endpoint: Infection rate. Started Nov 2022; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on TCTR20250428002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250428002.